Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The short ragweed (Ambrosia artemisiifolia) pollen-specific IgE-mediated immune response is a Type I hypersensitivity reaction triggered by exposure to ragweed pollen in sensitized individuals. This response involves the activation of Th2 lymphocytes, production of specific IgE antibodies, and subsequent release of inflammatory mediators from mast cells and basophils upon re-exposure to the allergen. The primary allergen, Amb a 1, plays a crucial role in this process. Management includes pharmacotherapy for symptom relief and allergen-specific immunotherapy to induce immune tolerance.
Antihistamines block histamine receptors; Corticosteroids reduce inflammation; AIT induces immune tolerance.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Short Ragweed (Ambrosia artemisiifolia) Pollen-Specific IgE-Mediated Immune Response (Ragweed IgE Response).